Ignite Creation Date:
2024-07-17 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06477055
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-06-19
Brief Title:
The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer
Sponsor:
Hunan Province Tumor Hospital
Organization:
Hunan Province Tumor Hospital
Study Overview
Official Title:
A Prospective Multicenter Phase II Study Evaluating the Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RAISE
Brief Summary:
This is a phase II prospective multicenter study to evaluate the recurrence gene profiles of adjuvant osimertinib therapy in resected EGFR-mutated NSCLC
Detailed Description:
This is aprospective multicenter phase II study to evaluate the recurrence gene profiles of adjuvant osimertinib therapy in resected EGFR-mutated NSCLC Approximately 60 NSCLC patients with EGFR-sensitive mutations 19del L858R who received adjuvant osimertinib after complete resection were enrolled The primary endpoint was to assess the recurrence gene profiles of adjuvant Osimertinib therapy The secondary endpoint was to explore of subgroups recurrence gene profiles of different recurrence types local distant after adjuvant Osimertinib therapy and to describe the diverse treatment patterns in real clinical practice after the disease progressed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None